The U.S. FDA has approved Novartis’ Cosentyx (secukinumab) for treating moderate to severe hidradenitis suppurativa (HS), a painful skin disease, making it the first new biologic treatment for the condition in nearly a decade. Before this, only AbbVie’s Humira was available as a biological treatment option for HS in the U.S. The approval of Cosentyx was based on data from Novartis’ late-stage SUNSHINE and SUNRISE studies, where it helped more patients achieve lesion reduction. Cosentyx may soon face competition from UCB’s bimekizumab, which has shown promising results in its trials. Despite this, Novartis is banking on additional indications for Cosentyx to secure its growth, potentially bringing an additional $2 billion in peak sales for the drug.
To read more, click here.
[Source: Fierce Pharma, November 1st, 2023]